Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome
Abstract Background No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical signifi...
Main Authors: | Nian-Peng Song, Xiao-Wen Zhen, Liu-dong Li, Lin Zhong, Hua Wang, Yi An |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-020-01717-5 |
Similar Items
-
“No-Reflow” Phenomenon: A Contemporary Review
by: Gianmarco Annibali, et al.
Published: (2022-04-01) -
Dilation of the Infarct-Related Coronary Artery to Reduce the Incidence of the No-Reflow Phenomenon in STEMI Patients
by: G. V. Sazanov, et al.
Published: (2023-08-01) -
Treatment Outcomes in STEMI Patients With No/Slow-Reflow Phenomenon, Depending on Age
by: G. V. Sazanov, et al.
Published: (2023-11-01) -
Evaluation of the clinical and procedural predictive factors of no-reflow phenomenon following primary percutaneous coronary intervention
by: Seifollah Abdi, et al.
Published: (2015-01-01) -
Utility of electrocardiogram to predict the occurrence of the no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention (PPCI): a systematic review and meta-analysis
by: Elmira Jafari Afshar, et al.
Published: (2024-01-01)